Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

Harvard Business School
Moodys
Colorcon
McKinsey
Merck
McKesson

Last Updated: August 19, 2022

Investigational Drug Information for LCB01-0371


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


What is the development status for investigational drug LCB01-0371?

LCB01-0371 is an investigational drug.

There have been 11 clinical trials for LCB01-0371. The most recent clinical trial was a Phase 2 trial, which was initiated on December 10th 2016.

The most common disease conditions in clinical trials are Tuberculosis, Pulmonary, Tuberculosis, and Infection. The leading clinical trial sponsors are LegoChem Biosciences, Inc, Ludwig-Maximilians - University of Munich, and Radboud University.

There are three US patents protecting this investigational drug and twenty international patents.

Recent Clinical Trials for LCB01-0371
TitleSponsorPhase
A Phase 2a Study, Effect of Vancomycin With vs Without Delpazolid (LCB01-0371) in Patients With MRSA BacteremiaLegoChem Biosciences, IncPhase 2
PanACEA DElpazolid Dose-finding and COmbination DEvelopment (DECODE)Ludwig-Maximilians - University of MunichPhase 2
PanACEA DElpazolid Dose-finding and COmbination DEvelopment (DECODE)Radboud UniversityPhase 2

See all LCB01-0371 clinical trials

Clinical Trial Summary for LCB01-0371

Top disease conditions for LCB01-0371
Top clinical trial sponsors for LCB01-0371

See all LCB01-0371 clinical trials

US Patents for LCB01-0371

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
LCB01-0371 See Plans and Pricing Oxazolidinone derivatives with cyclic amidoxime or cyclic amidrazone pharmaceutical compositions thereof Legochem Biosciences, Inc. (Deajeon, KR) See Plans and Pricing
LCB01-0371 See Plans and Pricing Therapeutic combination of daptomycin and protein synthesis inhibitor antibiotic, and methods of use Trius Therapeutics, Inc. (San Diego, CA) See Plans and Pricing
LCB01-0371 See Plans and Pricing Method for preparing (R)-3-(3-fluoro-4-(1-methyl-5,6-dihydro-1,2,4-triazin-4(1H)-yl)phenyl)-5-- (substituted methyl)oxazolidin-2-one derivatives Legochem Biosciences, Inc. (Daejeon, KR) See Plans and Pricing
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for LCB01-0371

Drugname Country Document Number Estimated Expiration Related US Patent
LCB01-0371 Australia AU2009297294 2028-09-24 See Plans and Pricing
LCB01-0371 Brazil BRPI0918964 2028-09-24 See Plans and Pricing
LCB01-0371 Canada CA2737299 2028-09-24 See Plans and Pricing
LCB01-0371 China CN102171207 2028-09-24 See Plans and Pricing
LCB01-0371 European Patent Office EP2331529 2028-09-24 See Plans and Pricing
LCB01-0371 Spain ES2526120 2028-09-24 See Plans and Pricing
LCB01-0371 Japan JP2012503599 2028-09-24 See Plans and Pricing
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Moodys
Colorcon
McKinsey
Merck
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.